Treatment of depressive disorders in Parkinson's disease;Medikamentöse therapie depressiver störungen beim Morbus Parkinson

Aktuelle Neurologie

Volumn 32, Issue 2, 2005, Pages 77-85

  Reiff, J ^a   Witt, K ^a   Deuschl, C ^a,b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DIBENZAZEPINE DERIVATIVE; DIBENZEPIN; DOPAMINE RECEPTOR STIMULATING AGENT; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LORAZEPAM; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PRAMIPEXOLE; REBOXETINE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE PLUS TRIFLUOPERAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

BECK DEPRESSION INVENTORY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARKINSON DISEASE; PATHOGENESIS; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

EID: 16244404597     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-834641     Document Type: Review

References (57)

1. Poewe W, Luginger E. Depression in parkinson's disease: Impediments to recognition and treatment options. Neurology 1999; 52: S2-6
2. Shiba M, Bower JH, Maraganore DM et al. Anxiety disorders and depressive disorders preceding parkinson's disease: A case-control study. Mov Disord 2000; 15: 669-677
3. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130-1133
4. Starkstein SE, Mayberg HS, Leiguarda R et al. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 377-382
5. Mayberg HS, Solomon DH. Depression in parkinson's disease: A biochemical and organic viewpoint. Adv Neurol 1995; 65: 49-60
6. Becker T, Becker G, Seufert J et al. Parkinson's disease and depression: Evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry 1997; 63: 590-596
7. Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology 1984; 34: 642-646
8. Mayberg HS, Starkstein SE, Sadzot B et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with parkinson's disease. Ann Neurol 1990; 28: 57-64
9. Menza MA, Palermo B, DiPaola R et al. Depression and anxiety in parkinson's disease: Possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 1999; 12: 49-52
10. Mossner R, Henneberg A, Schmitt A et al. Allelic variation of serotonin transporter expression is associated with depression in parkinson's disease. Mol Psychiatry 2001; 6: 350-352
11. Stern Y, Marder K, Tang MX, Mayeux R. Antecedent clinical features associated with dementia in parkinson's disease. Neurology 1993; 43: 1690-1692
12. Brown RG, MacCarthy B, Gotham AM et al. Depression and disability in parkinson's disease: A follow-up of 132 cases. Psychol Med 1988; 18:49-55
13. APA. Diagnostic and statistical manual of mental disorders. 1994
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
16. Leentjens AF, Verhey FR, Lousberg R et al. The validity of the hamilton and montgomery-asberg depression rating scales as screening and diagnostic tools for depression in parkinson's disease. Int J Geriatr Psychiatry 2000; 15: 644-649
17. Beck ATWC, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571
18. Zung W. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70
19. Bech PWL. Applicability and validity of the major depression inventory in patients with parkinson's disease. Nord J Psychiatry 1998; 52: 305-309
20. Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the beck depression inventory as a screening and diagnostic instrument for depression in patients with parkinson's disease. Mov Disord 2000; 15: 1221-1224
21. Bauer M, Whybrow PC, Angst J et al. World federation of societies of biological psychiatry (wfsbp) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43
22. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. J Clin Psychiatry 2001; 62, Suppl 16: 5-9
23. Kirchheiner J, Bertilsson L, Bruus H et al. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003: 36, Suppl 3: S235-243
24. Menza MA, Sage J, Marshall E et al. Mood changes and "on-off" phenomena in parkinson's disease. Mov Disord 1990; 5: 148-151
25. Allain H, Schuck S, Mauduit N. Depression in parkinson's disease. Bmj 2000; 320: 1287-1288
26. Shaw KMLA, Stern GM. The impact of treatment with levodopa on parkinson's disease. QJ Med 1980; 49: 283-293
27. Rogers DC, Costall B, Domeney AM et al. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology (Berl) 2000; 151: 91-97
28. Perugi G, Toni C, Ruffolo G et al. Adjunctive dopamine agonists in treatment-resistant bipolar ii depression: An open case series. Pharmacopsychiatry 2001; 34: 137-141
29. Ostow M. Pramipexole for depression. Am J Psychiatry 2002; 159: 320-321
30. Corrigan MH, Denahan AQ, Wright CE et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65
31. Lattanzi L, Dell'Osso L, Cassano P et al. Pramipexole in treatment-resistant depression: A 16-week naturalistic study. Bipolar Disord 2002; 4: 307-314
32. Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in parkinson's disease: A national multicentre prospective randomized study. EurJ Neurol 2003; 10: 399-406
33. Andersen J, Aabro E, Gulmann N et al. Anti-depressive treatment in parkinson's disease. A controlled trial of the effect of nortriptyline in patients with parkinson's disease treated with 1-dopa. Acta Neurol Scand 1980; 62: 210-219
34. Wermuth L, Sorensen PS, Timm B et al. Depression in idiopathic parkinson's disease treated with citalopram - a placebo-controlled trial. Nordic Journal of Psychiatry 1998; 52: 163-169
35. Rabey J, Orlov E, Korczyn AD. Comparison of fluvoxamine versus amitriptyline for treatment of depression in parkinson's disease. Neurology 1996; 46: A374
36. Shabnam GN, Chung TH, Deane KHO et al. Therapies for depression in parkinson's disease. Cochrane Database Syst Rev, 2003, CD003465
37. Emre M. What causes mental dysfunction in parkinson's disease? Mov Disord 2003; 18, Suppl 6: S63-71
38. Bedard MA, Pillon B, Dubois B et al. Acute and long-term administration of anticholinergics in parkinson's disease: Specific effects on the subcortico-frontal syndrome. Brain Cogn 1999; 40: 289-313
39. Bosboom JL, Stoffers D, Wolters E. The role of acetylcholine and dopamine in dementia and psychosis in parkinson's disease. J Neural Transm Suppl 2003; 65: 185-195
40. Emre M. Dementia in parkinson's disease: Cause and treatment. Curr Opin Neurol 2004; 17: 399-404
41. Sternic N, Kacar A, Filipovic S, Svetel M. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase a inhibitor, in parkinson's disease. Clin Neuropharmacol 1998; 21: 93-96
42. Stassen HH, Angst J, Szegedi A. How to assess the onset of antidepressant effect. Empirical data on 2788 patients. Pharmacopsychiatry 2003; 36: 265
43. Thase ME, Rush AJ. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58, suppl 13: 23-29
44. Strang RR. Imipramine in treatment of parkinsonism: A double-blind placebo study. Br Med J 1965; 5452: 33-34
45. Laitinen L. Desipramine in treatment of parkinson's disease. A placebo-controlled study. Acta Neurol Scand 1969; 45: 109-113
46. Steur EN. Increase of parkinson disability after fluoxetine medication. Neurology 1993; 2: 211-213
47. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G et al. Parkinsonism exacerbated by paroxetine. Neurology 1994; 44: 2406
48. Simons A. Fluoxetine in parkinson's disease. Movement Disorders 1996; 11: 581-582
49. Linazasoro G. Worsening of parkinson's disease by citalopram. Parkinson Rel Disord 2000; 6: 111-113
50. Ceravolo R, Nuti A, Piccinni A et al. Paroxetine in parkinson's disease: Effects on motor and depressive symptoms. Neurology 2000; 55: 1216-1218
51. Tesei S, Antonini A, Canesi M et al. Tolerability of paroxetinein parkinson's disease: A prospective study. Mov Disord 2000; 15: 986-989
52. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999; 53: 1154
53. Montastruc JL, Fahre N, Blin O et al. Does fluoxetine aggravate parkinson's disease? A pilot prospective study. Mov Disord 1995; 10: 355-357
54. McCance-Katz EF, Marek KL, Price LH. Serotonergic dysfunction in depression associated with parkinson's disease. Neurology 1992; 42: 1813-1814
55. Shulman LMSC, Liefert R. Therapeutic effects of sertraline in patients with parkinson's disease. Mov Disord 1996; 1: 12
56. Hauser RAZT. Sertraline for the treatment of depression in parkinson's disease. Mov Disord 1997; 12: 756-759
57. Lemke MR. Reboxetine treatment of depression in parkinson's disease. J Clin Psychiatry 2000; 61: 872